Wimits Pharmaceuticals Pvt. Ltd
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore pharmaceutical manufacturer producing human-health and veterinary medicines from a cGMP-oriented manufacturing facility.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Wimits Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 129, Sundar Industrial Estate, Lahore, Pakistan
- Website
- wimits.com ↗
- Phone
- +92 42 111 11 6366
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Wimits Pharmaceuticals Pvt. Ltd is priced against the market
13 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| MyatraSource observed | — | — | Injection | 2.5mlx5's | 085793Official source ↗ | No indexed price | — | — |
| Nitovir 200Source observed | — | 50 mg | Tablet | 120's | 103752Official source ↗ | No indexed price | — | — |
| OfaxSource observed | — | 200 mg | Tablet | 10's | 085807Official source ↗ | No indexed price | — | — |
| OraySource observed | — | 20 mg | Capsule | 14's | 077272Official source ↗ | No indexed price | — | — |
| OraySource observed | — | 20 mg | Capsule | 10's | 077272Official source ↗ | No indexed price | — | — |
| OraySource observed | — | 20 mg | Capsule | 100's | 077272Official source ↗ | No indexed price | — | — |
| OraySource observed | — | 40 mg | Capsule | 14's | 078730Official source ↗ | No indexed price | — | — |
| OraySource observed | — | 40 mg | Powder for injection | 1's | 121559Official source ↗ | No indexed price | — | — |
| OselmitSource observed | — | 75 mg | Capsule | 10's | 103753Official source ↗ | No indexed price | — | — |
| OximitSource observed | — | — | Injection | 2mlx5's | 103501Official source ↗ | No indexed price | — | — |
| OximitSource observed | — | — | Injection | 2mlx5's | 103502Official source ↗ | No indexed price | — | — |
| P-MaltSource observed | — | 50 mg/5 mL | Syrup | 60ml | 077268Official source ↗ | No indexed price | — | — |
| P-MaltSource observed | — | 50 mg/5 mL | Syrup | 120ml | 077268Official source ↗ | No indexed price | — | — |
| P-Malt TabsSource observed | — | 100 mg | — | 10's | 085805Official source ↗ | No indexed price | — | — |
| PivacanSource observed | — | — | Injection | 5's | 085801Official source ↗ | No indexed price | — | — |
| Quazim w/wSource observed | — | 1 % | Cream | 25gm | 115594Official source ↗ | No indexed price | — | — |
| QuwaSource observed | — | 25 mg | Tablet | 10's | 099725Official source ↗ | No indexed price | — | — |
| QuwaSource observed | — | 100 mg | Tablet | 10's | 099726Official source ↗ | No indexed price | — | — |
| Quwa XRSource observed | — | 200 mg | Extended-release tablet | 10's | 124466Official source ↗ | No indexed price | — | — |
| RiserSource observed | — | 1 mg | Tablet | 10's | 099741Official source ↗ | No indexed price | — | — |
| RiserSource observed | — | 2 mg | Tablet | 10's | 099742Official source ↗ | No indexed price | — | — |
| RiserSource observed | — | 3 mg | Tablet | 10's | 099743Official source ↗ | No indexed price | — | — |
| RiserSource observed | — | 4 mg | Tablet | 10's | 099744Official source ↗ | No indexed price | — | — |
| RoxwinSource observed | — | 250 mg | Tablet | 1's | 096742Official source ↗ | No indexed price | — | — |
| RoxwinSource observed | — | 250 mg | Tablet | 28's | 096742Official source ↗ | No indexed price | — | — |
| RoxwinSource observed | — | 500 mg | Tablet | 1's | 096743Official source ↗ | No indexed price | — | — |
| RoxwinSource observed | — | 500 mg | Tablet | 28's | 096743Official source ↗ | No indexed price | — | — |
| SartelSource observed | — | 80 mg | Tablet | 10's | 099710Official source ↗ | No indexed price | — | — |
| SartelSource observed | — | 80 mg | Tablet | 14's | 099710Official source ↗ | No indexed price | — | — |
| SartelSource observed | — | 80 mg | Tablet | 28's | 099710Official source ↗ | No indexed price | — | — |
| SartelSource observed | — | 40 mg | Tablet | 10's | 099712Official source ↗ | No indexed price | — | — |
| SartelSource observed | — | 40 mg | Tablet | 14's | 099712Official source ↗ | No indexed price | — | — |
| SartelSource observed | — | 40 mg | Tablet | 28's | 099712Official source ↗ | No indexed price | — | — |
| SartelSource observed | — | 20 mg | Tablet | 10's | 100897Official source ↗ | No indexed price | — | — |
| Sartel-A 10Source observed | — | 40 mg | Tablet | 10's | 123527Official source ↗ | No indexed price | — | — |
| Sartel-A 10Source observed | — | 40 mg | Tablet | 14's | 123527Official source ↗ | No indexed price | — | — |
| Sartel-A 10Source observed | — | 80 mg | Tablet | 10's | 123528Official source ↗ | No indexed price | — | — |
| Sartel-A 10Source observed | — | 80 mg | Tablet | 14's | 123528Official source ↗ | No indexed price | — | — |
| Sartel-A 5Source observed | — | 40 mg | Tablet | 14's | 123525Official source ↗ | No indexed price | — | — |
| Sartel-A 5Source observed | — | 80 mg | Tablet | 10's | 123526Official source ↗ | No indexed price | — | — |
| Sartel-D 40Source observed | — | 12.5 mg | Tablet | 14's | 123529Official source ↗ | No indexed price | — | — |
| Sartel-D 40Source observed | — | 12.5 mg | Tablet | 28's | 123529Official source ↗ | No indexed price | — | — |
| Sartel-D 80Source observed | — | 12.5 mg | Tablet | 14's | 123530Official source ↗ | No indexed price | — | — |
| Sartel-D 80Source observed | — | 12.5 mg | Tablet | 28's | 123530Official source ↗ | No indexed price | — | — |
| Solo-CipSource observed | — | 500 mg | Tablet | 10's | 077262Official source ↗ | No indexed price | — | — |
| Solo-CipSource observed | — | 250 mg | Tablet | 10's | 077263Official source ↗ | No indexed price | — | — |
| SyafenSource observed | — | 50 mg | — | 10's | 099722Official source ↗ | No indexed price | — | — |
| TazovexSource observed | — | 2.25 g | Injection | 1's | 127326Official source ↗ | No indexed price | — | — |
| TazovexSource observed | — | — | Injection | 1's | 127327Official source ↗ | No indexed price | — | — |
| Terfun w/wSource observed | — | 1 % | Cream | 15gm | 119679Official source ↗ | No indexed price | — | — |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.